The Cascade Advanced Energy Facility would use next-gen Xe-100 reactors to deliver 960 megawatts of carbon-free power — but it’s years from becoming reality.

Researchers in Germany have discovered that tiny quantum engines can beat traditional efficiency limits set by Carnot’s theorem.
EPFL researchers have demonstrated the first pill-sized bioprinter that can be swallowed and guided within the gastrointestinal tract, where it directly deposits bio-ink over damaged tissues to support repair.
Soft tissue injuries of the gastrointestinal tract, like ulcers or hemorrhages, can currently be treated only with some form of surgery, which is invasive and may not result in permanent repair. Bioprinting is emerging as an effective treatment that deposits biocompatible “ink”—often made of natural polymers derived from seaweed—directly over the site of tissue damage, creating a scaffold for new cell growth. But like traditional surgical tools, these kinds of bioprinters tend to be bulky and require anesthesia.
At the same time, “untethered” technologies are being developed to perform medical interventions without a physical connection to external equipment. For example, ingestible “smart capsules” can be guided to drug delivery sites using external magnets. But these devices are designed to travel through liquids, and their movements become unpredictable when they touch the tissue wall.